This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

UPC outlines next steps in Sanofi's prostate cancer drug dispute

( May 9, 2025, 09:09 GMT | Official Statement) -- MLex Summary: The Unified Patent Court’s Munich division has issued a procedural order in Sanofi’s ongoing litigation over European patent 2,493,466, covering a prostate cancer treatment. The order addresses formal issues in Sanofi’s claims against generic drugmakers including Accord, Stada, Reddy and Zentiva, who are accused of infringing the patent in several EU countries. The judge allowed amendments to continue proceedings and clarified requirements for damage claims and cost sharing. The order also confirmed a next hearing to take place in mid-October. The dispute centers on direct and indirect use of the patented treatment. The order is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections